NASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $82.07 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$82.03 -0.04 (-0.05%) As of 06/12/2026 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$77.16▼$83.6150-Day Range$76.42▼$95.7652-Week Range$16.64▼$96.50Volume1.38 million shsAverage Volume930,866 shsMarket Capitalization$4.49 billionP/E RatioN/ADividend YieldN/APrice Target$117.82Consensus RatingModerate Buy Company Overview Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 590th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingDianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $117.82, representing about 43.6% upside from its current price of $82.07.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -19.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -19.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.62% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 10.88, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 4.02%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.80 News SentimentDianthus Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dianthus Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,635,454.00 in company stock.Percentage Held by Insiders3.02% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Cartesian Therapeutics (RNAC) and Cullinan Management (CGEM)June 13 at 9:38 AM | theglobeandmail.comDNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study ResultsJune 12 at 7:19 PM | finance.yahoo.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free. | Behind the Markets (Ad)Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) NarrativeJune 9, 2026 | finance.yahoo.comDianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comDianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product PipelineJune 5, 2026 | insidermonkey.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of "Buy" from AnalystsJune 5, 2026 | americanbankingnews.comInsider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 26,530 Shares of StockJune 3, 2026 | insidertrades.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $41.21 on January 1st, 2026. Since then, DNTH stock has increased by 99.2% and is now trading at $82.07. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.22. The company earned $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 27.30% and a negative net margin of 12,998.50%. When did Dianthus Therapeutics IPO? Dianthus Therapeutics (DNTH) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Dianthus Therapeutics' major shareholders? Dianthus Therapeutics' top institutional shareholders include Octagon Capital Advisors LP (3.56%), Jennison Associates LLC (0.89%), Spruce Street Capital LP (0.68%) and Dimensional Fund Advisors LP (0.60%). Insiders that own company stock include Fairmount Funds Management Llc, Ryan Savitz, Simrat Randhawa, Marino Garcia and Edward Carr. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/05/2026Today6/14/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 DNTH's financial health is in the Green zone, according to TradeSmith. DNTH has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$117.82 High Price Target$145.00 Low Price Target$98.00 Potential Upside/Downside+43.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.34 million Net Margins-12,998.50% Pretax Margin-12,998.50% Return on Equity-27.30% Return on Assets-25.91% Debt Debt-to-Equity RatioN/A Current Ratio29.25 Quick Ratio29.25 Sales & Book Value Annual Sales$2.04 million Price / Sales2,199.40 Cash FlowN/A Price / Cash FlowN/A Book Value$11.41 per share Price / Book7.19Miscellaneous Outstanding Shares54,670,000Free Float53,015,000Market Cap$4.49 billion OptionableOptionable Beta1.18 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:DNTH) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
